Participated · Equity · Jul 2026

Health Triage develops artificial intelligence-based diagnostic tools for oncology and is advancing proprietary projects named Breast Negative and Prostate V-Bio. The company aims to validate its technologies clinically and integrate them into hospital workflows to make AI a routine clinical standard. Management has pursued industry-aligned financing, securing a €5M strategic investment from Fondazione ENEA Tech and Biomedical last year and a further €3M equity infusion from Vertis SGR and Health 1. Reported uses of funds include organic development of projects, ongoing clinical validation, integration into clinical workflows, market analysis, and exploration of therapeutic applications beyond diagnostics. Leadership emphasizes combining scientific rigor with industrial vision to support adoption and potential internationalization. Fin Posillipo S.p.A. is described as a supportive industrial partner in the company’s growth trajectory.